Open access peer-reviewed chapter - ONLINE FIRST

From Open to Minimally Invasive: The Sacrocolpopexy

Written By

Adriana Fulginiti, Frank Borao, Martin Michalewski and Robert A. Graebe

Submitted: October 2nd, 2021Reviewed: October 20th, 2021Published: March 16th, 2022

DOI: 10.5772/intechopen.101308

IntechOpen
Hysterectomy - Past, Present and FutureEdited by Zouhair Amarin

From the Edited Volume

Hysterectomy - Past, Present and Future [Working Title]

Prof. Zouhair Amarin

Chapter metrics overview

35 Chapter Downloads

View Full Metrics

Abstract

With an increased demand for pelvic organ prolapse surgeries as the population ages, mesh-related osteomyelitis will become more prevalent. This case series enriches the paucity of data on management options for delayed osteomyelitis related to pelvic organ prolapse mesh. A literature review revealed no case reports of delayed onset osteomyelitis presenting up to a decade after colpopexy mesh placement. We present three cases of delayed osteomyelitis, their presentation, diagnosis and management at a tertiary academic referral center. Patients presented between 1 and 10 years after mesh colpopexy. Three different mesh materials were utilized during the initial procedures: Restorelle Y, Gynamesh and Gore-Tex mesh. The first case demonstrates failed expectant management with eventual surgical intervention on a medically compromised patient. The two subsequent cases describe elective complete mesh resection after several prior failed mesh revision attempts. This short case series and literature review illustrates that mesh-related osteomyelitis after a remote sacrocolpopexy carries significant morbidity. Mesh removal by means of minimally invasive surgery in the hands of an experienced surgical team utilizing DaVinci Robotic System is a good option and may lead to best patient outcomes.

Keywords

  • Sacrocolpopexy
  • mesh
  • Urogynecology
  • robotic
  • osteomyelitis
  • erosion

1. Introduction

Arthure first described a method of fixating the prolapsed uterus to the sacral promontory in 1957 [1] and Lane introduced the concept of vaginal apex or uterine suspension to the sacral promontory using an intervening graft in 1962 [2]. The abdominal sacrocolpopexy (ASC) is the most durable repair for advanced pelvic organ prolapse (POP) and became the gold standard surgical treatment for apical vaginal defects, with long-term success rates of 78–100% [3, 4, 5, 6]. Although ASC was established as the most durable operation, the morbidity associated with laparotomy limited its broad use especially in the elderly, obese or in women with significant medical comorbidities [5, 7]. In the last two decades, minimally invasive approaches have been widely accepted as an alternative option to ASC [8, 9, 10]. Laparoscopic sacrocolpopexy (LSC) was first reported in 1994 by Nezhat [11]. Robotic Assisted Sacrocolpopexy (RAS) was described a decade later by DiMarco [12] in 2004. Since the Food and Drug Administration (FDA) approval of the DaVinci Surgical system (Intuitive Surgical, Inc., Sunnyvale, CA) for gynecological operations in 2005, it has become a fundamental part of the armamentarium in complex pelvic floor procedures [13].

Compared to the abdominal route, minimally invasive sacrocolpopexies are more costly and can be more time consuming in the inexperienced hands. Level I evidence from as early as 2012 supported LSC as the lower-risk option with improved anatomic and subjective outcomes, lower recurrence rates, less post-operative dyspareunia, less blood loss and faster recovery [4, 7, 14, 15]. Maher et al.’s randomized clinical trial demonstrated shorter hospital stay, earlier return to daily activity, improved anatomical outcomes, and less graft-related complications. There were also less re-interventions and related hospital costs, which ultimately outweighed longer operation times [15].

The limitation to wide acceptance of laparoscopic reconstructive pelvic surgery was the need for advanced surgical skill to dissect the pre-sacral space and suture mesh graft to the vagina and sacrum, which many surgeons found too arduous or time consuming to perform. Data shows that approximately 30 LSCs need to be performed to achieve an operation time comparable to an experienced surgeon, and about 60 are needed to obtain similar complication rates [7]. Long-term evidence across all surgical disciplines unequivocally shows that outcomes of high volume surgeons are superior, with lower complication rates [16, 17].

The number of women undergoing Pelvic Organ Prolapse (POP) procedures is estimated at 400,000 annually in the U.S. and an additional 260,000 for stress urinary incontinence (SUI) [18, 19, 20]. Over 50% of women over 65 years have some form of urinary incontinence. It is predicted that by 2030, about 20% of the U.S. population will be within this age group, increased from 13% in 2010 [21]. With aging demographics, the national burden related to pelvic floor disorders (PFD), decreased quality of life, and demand for pelvic floor surgeries is expected to increase. In 2010 there were 1,218,371 new pelvic floor-related patient visits in the U.S. [22]. The U.S. Census and NHANES data estimates that the number of women with PFD is expected to reach 43.8 million by 2050 [23]. With more cases of intra-abdominally placed mesh for POP, and with robotic advancements, it is expected that there will be an increased number of complications such as lumbosacral osteomyelitis [20]. Mesh associated osteomyelitis has been reported in only a few cases, with none presenting up to a decade after mesh placement.

Prosthetic vaginal mesh for POP repairs was introduced in the 1990s, and became liberally used in the mid 2000s, aiming to replace long and complex intra-abdominal procedures. In 2004 FDA approved vaginal meshes as POP repair kits. This resulted in standardization of surgical techniques across the U.S. and allowed for more robust research [24, 25]. Introduced by American Medical Systems (San Jose, CA), Apogee and Perigee systems were the first ready-to-use pelvic mesh repair kits commercially available in 2005 [24]. Shortly after they were followed by the most widely used Gynacare Ethicon’s Prolift kits (Johnson and Johnson, Sommerville NJ) and many others such as C.R. Bard, Boston Scientific, Coloplast, and Cook Medical [24, 25]. Mesh kits were brought to the market relatively fast, and as the Gartner curve shows with most innovations, industry hype and corporate avarice lead to mass marketing, and drawbacks become clear when use of mesh became more widespread [26]. Between 2005 and 2010 in the U.S., J&J Ethicon’s Gynacare division sold over $1 Billion worth of female POP repair mesh products alone.

Direct and aggressive marketing by large corporation sales-representatives to inadequately trained in pelvic reconstructive surgery ObGyns and general Urologists led to inappropriate procedures. Often after a minimal “training course” and/or cadaver lab, many physicians became “mesh repair specialists” advertised by the product manufacturer. Regretfully, repairs for prophylactic reasons or due to peer pressure, and use of mesh simply to boost revenue from anterior-posterior repairs became common. Increased complication rates and reports of significant patient morbidity became evident. Bleeding (0–3%), visceral injury (1–4%), urinary infection (0–19%), graft erosion (0–30%), and fistula formation (1%) led to FDA review of Urogynecologic mesh products [19, 27]. There was a five-fold increased complication rate from 2005 to 2007 compared to the previous three years [19]. From October 2008 to 2011, surgical mesh outcomes were scrutinized, revealing an additional 2874 reports of adverse events with POP mesh repairs, and 1371 with stress urinary incontinence (SUI) repairs, resulting in the FDA advisory warning: “complications of POP repairs with mesh are not rare and may be difficult to treat” [19].

The most frequently reported issues were urinary tract infections (UTI), urinary retention, mesh erosion, dyspareunia, bleeding, and organ perforation. More than half of women with erosion from non-absorbable synthetic mesh required surgical removal [19, 28, 29, 30]. There were seven reported deaths from POP repairs [19]. The FDA conducted a scientific literature review from 1996 to 2011, which showed that symptomatic results or quality of life were not improved with use of mesh versus the traditional native repair [31]. In light of this, the FDA reclassified mesh for transvaginal repair from Class II to Class III “High Risk”, which required manufacturers to submit premarket approval applications [19]. In 2012, J&J Ethicon and C.R. Bard were first to voluntarily remove their POP mesh kits from the markets due to increased litigation and diminishing profits [18, 32]. Ethicon’s Gynemesh and Coloplast’s Restorelle are still in use, although with a future still uncertain [19].

Women are exposed to lawsuit advertisements in various media focused on complications of surgical mesh, and presented with tragic, yet often, anecdotal stories [26, 33, 34]. While acknowledging these warnings, many organizations have missed the opportunity to proactively confront the vaginal mesh debate. Instead of gathering surgeons and industry together to improve the use of mesh, initiate protocols for selecting optimal surgical candidates, and standardize recommendations for surgeon credentialing, pelvic mesh kit manufacturers have succumbed to the bans and quickly settled ensuing tort case law suits. The biggest companies such as Johnson & Johnson moved towards more lucrative “new” non-surgical treatment options such as anti-incontinence vaginal inserts and pessaries. Treatments became focused on pelvic floor muscle strengthening with adjunctive therapies, vaginal cones, kegel chairs, laser vaginal rejuvenation and electrical muscle stimulation devices whose benefits are often difficult to substantiate [35, 36]. From vaginal pessaries first described in 1550 BC [20], the market has expanded to include vaginal rings, self-powered wireless urinary incontinence sensors for disposable diapers [37], and intra-vaginal inserts. Adult diapers has become the next multi-billion dollar industry as they were aggressively advertised and fast out-paced infant diaper sales in the U.S. [35]. In 2012, the North American market for adult incontinence pads and diapers sold 11 billion units worth $4.42 billion [38]. Major personal care brands such as Depend, Poise, and Tena are aimed to remove the social stigmatism around incontinence, with advertisement campaigns and product launches targeting the boomer generation [38]. Young athletes and celebrities are used in late-night advertisements to influence women of all ages [31, 33, 34, 38].

The first decade of the twenty-first century was also a time of fast-paced technological advancement. With increased equipment availability and acceptance within the surgical community of DaVinci robotic surgical systems in mid 2000s, the use of robotic technology made LSC a more accessible procedure. These advancements permitted precise and intuitive movements, allowing suturing of mesh to the vagina with relative ease for more practitioners [3, 7, 39, 40]. Improved ergonomics and the three-dimensional viewing of the robotic system provided better visualization of tissue planes and vasculature near the sacral promontory, allowing for faster dissection and overall safer procedures with less blood loss and better outcomes [3]. Robotic wristed instruments improved dexterity, requiring fewer cases to gain surgical competence, and became more attractive in a wider number of surgical theaters [7, 39, 40]. There is paucity of data comparing patient outcomes between laparoscopic and robotic assisted sacrocolpopexies (RAS). The randomized controlled ACCESS trial demonstrated that RAS are more costly than LSCs ($19,616 vs. $11,573, p < 0.001) [3, 7] with no difference in procedure time (225 vs. 246 min p = 0.110), anatomical outcomes, pelvic floor function, or quality of life [3, 7].

While vaginal mesh complications are extensively researched and publicized, research data of intra-abdominally placed mesh for pelvic floor repairs issues are obscure [8, 40, 41]. Descriptions of mesh problems associated with placement by endoscopic procedures are even more rare. Available data pertains to the risks that are mostly those specific to laparoscopy, use of general anesthesia, pneumoperitoneum and prolonged Trendelenburg positioning [42, 43]. Complications of vaginal POP repairs with mesh are widely reported, however, what is attributable to poor technique versus mesh itself is debatable. Published data from self-proclaimed “mesh removal experts” confirm this. Margulies et al. (a vocal critic of vaginal mesh and a prominent plaintiff expert), identified mesh folding at the time of mesh excision surgery in 69% of patients who had their mesh removed due to dyspareunia [44]. During Crosby’s surgeries for mesh removal, he also found that mesh to be folded or had significant tension in 70% of his patients [45].

Cho et al. performed a large case review to compare LSC to the traditional open procedure. There were no significant intraoperative complications other than a 1.08% risk of blood transfusion, and a low rate of postoperative complications (8% constipation, 4% lower abdominal discomfort, 5% urge incontinence, 4% vaginal spotting, and less than 3% for all other complications) [43]. Meticulous mesh placement and improved visualization resulted in good long-term outcomes (0% relapse rate at 1 year) [20]. 98.8% of women were satisfied with their surgical outcome, with no reports of sexual dysfunction [43]. Altogether, these results show that the minimally invasive approach has better outcomes comparable to the abdominal approach, and is also significantly safer and more efficient [46]. In view of medico-legal climate and with politically prevailing negative opinions of vaginal mesh, abdominally placed mesh via minimally invasive surgery for POP is safe, durable, and currently the best option. As in any mesh/implant surgery, patient selection, surgical field sterility, avoidance of excessive electrocautery, clear planes of dissection, meticulous hemostasis and proper mesh placement are of the uttermost importance [44, 45].

With the vaginal mesh industry on hold, many prominent pelvic surgeons reverted to intra-abdominal repairs. The options range from the classic sacrocolpopexy in which the vaginal cuff after hysterectomy is affixed to the anterior longitudinal ligament (ALL) with permanent sutures and Y-shaped mesh graft [9, 47], to uteropexy to preserve fertility [47]. These repairs can be done with sutures, with or without mesh graft [9, 47]. Variants of the repair include sacral cervicocolpopexy, now the most commonly utilized by FPMRS specialists in the U.S., in which preservation of the cervical stump during hysterectomy facilitates suturing of the vaginal apex to ligaments [10]. This procedure is easier and safer, reduces operating times, and decreases the risk of mesh complications five fold [10]. Other options are sacrocolpoperineopexy [10] or modification of anterior or posterior rectopexy [48]. The choice of the procedure depends on patient site-specific defects and the comfort of the operating surgeon. There is also colpopectopexy, a modification of the apical vaginal suspension where the lateral aspects of the illiopectineal ligaments are used for unilateral or bilateral fixation of prolapsing vagina, which gained some hold first in Europe and later in the.

U.S. [49] (Case 2). Advancements in MIS, robotics and laparoscopy continue with the fast pacing introduction of better visualization systems, artificial intelligence, machine learning, computer enhanced surgery and integration of imaging studies into the live surgical field.

Complications of Minimally Invasive Surgery (MIS) with mesh for POP, diagnostic modalities, findings and management protocols are under-publicized. In 2011, Smith and Davila proposed a vaginal approach on how to manage small versus large mesh exposures, mesh contractions and infection, and also recommended preventative strategies [50]. However, reports are still lacking on how to manage infected mesh deep in the sacral region. Our three cases demonstrate that laparoscopic and robotic approaches to intra-abdominal mesh complications are feasible and can be utilized in a safe, efficient, and effective manner in the proper surgical setting. The described cases attempt to shed light on delayed onset osteomyelitis of the lumbosacral vertebrae, one of the rarely reported, but morbid complications of sacrocolpopexy. Its presentation, complications, and complexity of the intraoperative field are reviewed. As the use of permanent sutures and mesh implants in the vicinity of ligaments and bone increases, potential for osteomyelitis will increase. FPMRS surgeons applying mesh to the intra-peritoneal cavity must be extra vigilant in timely recognition and treatment of this once rare condition [14, 27].

A literature search showed that there is no case report of delayed onset osteomyelitis presenting up to a decade after mesh placement. We present three cases of osteomyelitis including presentation, diagnosis and management from a tertiary academic referral center. Patients presented between 1 and 10 years after mesh colpopexy procedure. Three different mesh materials were utilized during the initial POP repair procedures: Restorelle Y, Gynamesh and Gore-tex mesh.

The first case demonstrates failed expectant management followed by surgical intervention on a medically compromised patient, whereas the two subsequent cases describe elective surgical repairs undertaken after several prior failed mesh removal attempts. All cases were successfully managed by a multidisciplinary surgical team, completely resecting infected meshs utilizing DaVinci Xi Robotic System.

Case 1: Chronic urinary tract infection and back pain, vaginal malodorous discharge and pulmonary embolism.

74yo white female with a history of 4th degree uterovaginal prolapse who underwent DaVinci assisted laparoscopic sacral colpopexy and laparoscopic supracervical hysterectomy (LSC/LSH/BSO) with Restorelle Y polypropylene mesh (Coloplast) in 2015. Eightheen months after surgery the patient presented to a local emergency room with lower back and abdominal pain. She was diagnosed with UTI and discharged home on oral antibiotics. She presented 1 month later to our institution with fever and a history of chronic UTI, worsening back pain and generalized weakness. She was admitted by for intravenous antibiotics with presumptive diagnosis of pyelonephritis complicated by urosepsis. During her workup it was discovered that she also had a pulmonary embolism and was treated accordingly.

Computed Tomography (CT) scan showed hyper-enhancement of the lumbar sacral joints L5 to S1, with Magnetic Resonance Imaging (MRI) noted a well-defined enhancing fistulous tract from the lumbosacral region to the vaginal space consistent with discitis and osteomyelitis (Figure 1A and B). The patient’s mental status was slightly impaired either due to age, delirium from nicotine withdrawal, or current medical condition. She was a heavy lifetime smoker with history of chronic obstructive pulmonary disease (COPD), a non-compliant patient and poor historian. Her pulmonary embolus was treated, she was kept on IV antibiotics for the discitis, the fever subsided, and the patient condition was stabilized. She then developed a new onset of malodorous vaginal discharge. Patient’s family reported a history of prior POP mesh repair. Urogynecologic and Spine surgeons were consulted at that time and vaginal examination showed apical abscess with copious foul discharge.

Figure 1.

(A and B) MRI showing discitis and osteomyelitis.

Diagnosis of a lumbosacral-peritoneal-vaginal fistula tract with mesh erosion was made. Despite 2 weeks of intravenous (IV) broad-spectrum antibiotic therapy, there was lack of improvement in pain, copious daily drainage increased and lumbosacral osteomyelitis worsened. Patient had developed local neurological deficits in the lower extremities compromising her ability to stand up and she could no longer walk. Spine surgical intervention became urgent and despite serious medical comorbidities, in consultation with General surgery and Urogynecology, it was determined that surgical removal of the infected mesh, fistula resection, abscess evacuation, and bone debridement could no longer be further delayed.

Intra-operatively, a vaginal fistulous connection was identified when a probe was passed through the vagina and was visible intra-abdominally to the pre-sacral lumbar bone space (Figure 2A). Using DaVinci assisted laparoscopy, adhesions were freed of the involved bowel, and the infected mesh was removed and abscess drained (Figure 2B). The bladder and ureter were dissected with illuminated stents in place. Bone debridement was performed and osteopromotive materials were grafted onto the L4 to S1 posterior lumbar region by Spine and Vascular Surgeon, who dissected and patch repaired the left common iliac vein in the process to completely remove mesh from the lumbosacral area. Total operating time of 180 min. The patient was kept on IV antibiotics and anticoagulation for 6 weeks postoperatively while recovering at a nursing facility. She was home in 6 weeks time living independently. Unfortunately she was a heavy smoker with poor hygiene and severe COPD that succumbed to pulmonary complications about 9 months later, albeit unrelated to her surgery.

Figure 2.

(A) Probe in fistula canal tracking to ischiopubic bone and iliopectineal ligament (laparoscopic view) and (B) mesh removed from vaginal cuff.

Case 2: Pelvic pain with persistant right groin/inguinal skin draining sinus tract. History of four failed fistula repairs, ventral and inguinal hernia.

A 70 year-old white female presenting with a right groin/inguinal draining sinus tract and ventral hernia complaining of pelvic and abdominal pain. She had a history of a total abdominal hysterectomy and an open colpopectopexy with Gore-Tex mesh performed in 2005. Subsequently, over the past 5 years she underwent multiple partial mesh revisions and three failed open peritoneo-cutaneous fistula tract repairs. After numerous second opinions, the patient was referred to our center. The patient presented in 2019 with complaints of abdominal, pelvic pain and chronic persistent groin discharge requiring several pads per day, compromising her daily activities. In the few months prior she also developed a painful lower abdominal bulge. Based on physical examination and CT scan, the patient was diagnosed with an eight-centimeter incarcerated ventral hernia (Figure 3A) with a patent fistulous tract from the groin to the upper vagina and intraperitoneal space, draining proximal to the bladder (Figure 3B).

Figure 3.

(A) Outside view of pelvic bulge, (B) laparoscopic view of the hernia after bowel loops reduction, (C) probe in fistula canal tracking to ischiopubic bone and iliopectineal ligament and (D) old Gortex suture material removed from bone defect.

Elective robotic repair of the incarcerated ventral hernia and mesh resection with fistula repair was performed. Upon laparoscopic entry, extensive adhesions were noted with loops of small bowel in the hernia sac. A right ureteral lighted stent was inserted illuminating the area of the bladder that was involved in the hernia sac. Under direct laparoscopic and cystoscopic guidance a blunt probe was inserted into the right groin sinus tract opening, mapping the fistula tract to the right pubic bone and right iliopectineal ligament immediately adjunct to bladder and right upper vagina.

The ventral and inguinal hernias were reduced and the fistula tract was dissected noting Gore-Tex mesh and suture material adherent to the inner aspect of the iliopubic bone, its periosteum, bladder and vagina (Figure 3C). There was a defect found in the right pubic bone approximately three-centimeter in size with granuloma tissue formation on the mesh that was also involving bone (Figure 3D). Bone debridement was performed and cultures showed heavy growth of Serratia Marcescens (SM), pathognomonic to nosocomial infections [51].

The cutaneoperitoneal tract and vesicovaginal defects were resected and repaired. Cystoscopy with hydrodissection and lighted ureteral stents assured bladder and right ureter integrity. The pubic bone defect was irrigated with antibiotic solution and packed with bone wax. The ventral and right inguinal hernia was repaired creating myofascial advancement flaps. A wound vacuum was applied at a pressure of 125 mmHg (Figure 4). Total operating time of 75 min. She was discharged after 24 h.

Figure 4.

Wound vacuum at a pressure of 125 mmHg.

Case 3: Pelvic pain, vaginal bleeding, dyspareunia, and chronic vaginal discharge.

52 year-old white female with a history of two prior cesarean sections and DaVinci LSC with Gynecare Y mesh and total laparoscopic hysterectomy (TLH) in 2012 complicated by vaginal apex mesh erosion which caused recurrent vaginal bleeding, dyspareunia and chronic UTI. She had two separate vaginal mesh revisions in 2017 that were further complicated by acute post-surgical intra-abdominal bleeding requiring return to the OR for bladder hematoma evacuation and blood transfusion. The patient presented 2 years later in 2019 complaining of chronic malodorous vaginal discharge, dyspareunia, post-coital bleeding and severe pelvic pain. Vaginal examination revealed copious foul-smelling discharge originating from a necrotic upper vagina with discolored vaginal mesh and pus.

Cultures of the discharge were collected, resulting in heavy growth of Group B Streptococcus and Bacteroides Ovatus. CT scan showed an intra-peritoneal pelvic abscess extending from the presacral space to the upper vagina. Although CT did not identify discitis, an MRI was recommended for evaluation of osteomyelitis that could not be ruled out due to swelling. Since the complications of mesh significantly impacted her quality of life and led to loss of consortium, the patient elected for mesh removal.

Upon laparoscopic evaluation, multiple loops of small bowel were adherent to the pelvic sidewall, occluding the anterior and posterior cul-de-sacs (Figure 5A). Frozen pelvis was encountered with dense adhesions of the recto-sigmoid with non-visualization of the sacral promontory. Extensive enterolysis was performed to gain access to the eroded and infected vaginal mesh and pelvic abscess (Figure 5B). Multiple loops of the small bowel and rectosigmoid colon were freed from the mesh, presacral space, vagina, bladder and ureter.

Figure 5.

(A) Dissection of rectosigmoid colon off vaginal cuff/mesh complex, (B) mesh exposed, (C) vaginal cuff with eroded mesh dissected off the pelvic promontory and (D) vaginal cuff closure in layers utilizing the DaVinci Robot.

Laparoscopic access to the infected Gynecare mesh allowed for evacuation of the intra-abdominal abscess. Once the infected graft was removed, upper vaginectomy and drainage of the pelvic abscess were performed (Figure 5C). The anterior longitudinal ligament appeared to be inflamed but not grossly infected. All old fixation sutures were cut and removed.

Early and aggressive intervention in this case prevented progression of upper necrotizing vaginal abscess ascending on the mesh and braided suture (Ethibond) “ladder” into the anterior longitudinal ligament and periostium of the sacral and lumbar vertebra. DaVinci Xi Robotic system was utilized for the resection of peritoneo-vaginal fistulous tract, entire mesh, upper vaginectomy, and cuff closure (Figure 5D).

Integrity of the bladder and rectum were confirmed by cystoscopy and proctosigmoidoscopy. The patient was discharged home 6 hours later and remains asymptomatic for over 1 year.

Advertisement

2. Discussion

Laparoscopic sacrocolpopexy with synthetic mesh is an effective treatment option for POP with success rates ranging from 78 to 100% [49, 52]. Manufacturer data shows that synthetic mesh can induce an inflammatory process that can result in fibrosis and scarring, distorting normal anatomy and changing the mesh characteristics [45]. Mesh exposure after POP or SUI procedures ranges from 2 to 30% [52], with reoperation rate of 7.9% for apical and 12.7% for other compartments repair as per Cochrane review [51]. Infected and/or exposed mesh can erode into nearby bone and periostium and cause osteomyelitis. Jenson’s report states that lumbosacral osteomyelitis and discitis usually occur by hematogenous spread but can also occur from direct inoculation after SCP when bone anchors or permanent sutures are inadvertently placed too deep into the L5-S1 disc space. Mesh exposure is also associated with chronic cigarette smoking, which may have had significance for the patient of Case 1 [53]. Osteomyelitis has been reported to have a median time of presentation of 4 months following a POP procedure [8, 32]. Our cases show that it can present up to 10 years later.

In 1997, Amid et al. classified mesh into different types. Type I mesh are monofilament, flexible and light-weight. They are recommended for most pelvic organ reconstructive procedures because their large pore size greater than 75 mcg allows for tissue integration and for immune cells to scavenge bacteria [54, 55]. Examples are polypropylene Restorelle mesh (used in Case 1), Gynemesh (used in Case 3), Atrium, and Marlex. Type II are microporous with pores less than 10 mcg, such as Gore-Tex (used in Case 2). Type III are microporous but with macroporous components, and type IV mesh are nonporous such as Silastic, Celligard, and Preclude [54, 55]. There lacks a clear recommendation on how to proceed with mesh exposure, especially for type I mesh. These cases add to the available literature regarding different types of mesh, their delayed complications, and treatment suggestions.

All data clearly shows that surgery is necessary when conservative measures fail, when there is high suspicion for severe osteitis, or when repeat mesh revisions are not successful. Surgery can occur via transvaginal excision, endoscopic assisted transvaginal excision, open laparotomy, or by minimally invasive intraperitoneal laparoscopic or robotic surgery. A literature review on the topic reveals no standard protocol for osteomyelitis related to POP-mesh [52, 56, 57, 58]. In February 2020, American Society of Obstetrics and Gynecology (ACOG) and International Urogynecological Association (IUGA) published a Joint Position to guide the management of mesh complications [57, 58]. Asymptomatic mesh exposure after SCP can be observed (Grade C recommendation) while understanding that three of four exposures will not resolve and may require surgery [57], which heals 93% of patients [59]. Similarly, Abbott et al. demonstrated that 60% of patients with mesh exposure need at least one surgical intervention to remove the mesh [60]. The 2019 National Institute for Health and Care Excellence recommends surgical intervention after 3 months of conservative management [57].

The patient of Case 1 underwent a trial of conservative management with antibiotics, however she required surgery once her clinical status acutely worsened. This patient became medically compromised, developed focal neurological deficits and her infection fistulised resulting in copious malodorous vaginal discharge leading to perineal excoriation.

Cases 2 and 3 presented patients requesting definitive surgical management after prior multiple failed mesh revisions attempts. Partial removal of mesh and the involved vaginal epithelium may be adequate for cases of limited vaginal exposure without pain (Grade D recommendation). However, office trimming with or without estrogen has a 75% risk of failure [18, 57, 61]. Repetitive trimming in the office is not recommended since it can distort the anatomy further (Grade D recommendation). According to the Joint Position, those who undergo surgical revision rather than office based trimming will still need additional surgery or complete excision in 37–50% of cases (Grace C recommendation). Focal vaginal pain without mesh exposure may require surgery if conservative measures are unsuccessful [57]. About 50% of patients undergoing mesh revision are successfully treated, but most require an abdominal surgery, and 25% require more than one surgery [57]. For persistent mesh-related pain, 50% of women with silicone mesh who attempt vaginal-specific repair ultimately need complete abdominal excision [57]. Cases 2 and 3 required complete intraperitoneal access removal of infected mesh after prior vaginal resection failures.

All above cases developed pelvic abscesses. Although there are reports of abscesses successfully managed by drainage alone (Grade C), these cases occurred within 14 days of SCP surgery [57]. Data is lacking for abscesses with delayed presentation, for which we recommend surgical intervention when conservative or partial-surgical interventions fail, or when severe symptoms persist. In those cases entire mesh must be removed. Similar to case 2 and 3 Unger et al. published a case of Gore-Tex soft tissue patch case that subsequently need complete removal after prior failed surgical attempts to partially remove it [24]. Our cases differ due to their prolonged interval from mesh placement to the time of osteitis. In these situations, surgeons should expect a chronically inflamed, distorted surgical field and must plan in advance to have different specialists equally involved and readily available.

In a patient with back pain and a history of SCP mesh, osteitis should be high on the differential given that 85% of SCP-osteitis cases present with back pain [62]. Physical exam with MRI of the lower spine is the gold standard for diagnosis [62]. Cultures can be helpful in directing targeted antibiotic therapy. Although some reported cases have responded to antibiotics alone (Grade I recommendation), most cases need multidisciplinary surgical team (Grade B recommendation), as this could be a life threatening condition [62]. The 2015 Infectious Disease Society of America (IDSA) recommend image-guided aspiration biopsy for patients with suspected vertebral osteomyelitis except when S. Aureus, S. Lugdunensis, or Brucella species are grown from blood cultures. However Jenson et al. recommends immediate empiric antibiotics to prevent infection along the spine [62]. Pathogens most commonly identified are staphylococcus and streptococcus, however fecal contamination may also be present in cases where a fistula is involved. Serratia Marcescens (SM) is a rod-shaped Gram-Negative facultative anaerobic, a rare bacterium that can cause osteomyelitis, particularly associated with IV recreational drug use or nosocomial infections [13]. SM fimbriae allow it to grasp onto surfaces, and its proteases enable it to thrive in anaerobic and aerobic environments [14]. Being intrinsically resistant to several beta-lactam antibiotics, first-line agents are instead Piperacillin-Tazobactam, a fluoroquinolone, an aminoglycoside, or a Carbapenem [14]. The regimen can then be tailored to susceptibility results. Given the nature and extent of infection, treatment requires 6–8 weeks of IV antibiotics, with most patients subsequently prescribed oral antibiotic therapy for a total duration of 12 weeks [8, 32, 63]. Case 2 demonstrates the aggressiveness of SM in the context of hospital-acquired infection, as it indolently grew and weakened the abdominal fascia causing incarcerated central hernia. This patient required a wound vacuum skin closure to allow repair sites to heal by secondary intention.

In presence of a severe infection, impaired mental capacity of elderly women may limit the ability to differentiate dementia from worsening sepsis. Individuals with history of POP mesh repairs with pain, abnormal vaginal discharge or bleeding discitis should have osteomyelitis high on the list of differentials and antibiotics should be initiated promptly if warranted. Consultation of FPMRS specialist familiar with above presentation along with physical exam and pelvic MRI helps for prompt diagnosis [53, 57]. Large mesh exposures, infection, severe symptoms, or involvement of bladder, bowel or bone require complete excision, understanding that complete removal of infected mesh from the posterior cul-de-sac in vicinity of the bladder and presacral space requires intra-abdominal access [57, 61]. Special attention must be paid to the bladder, ureters, rectum, and vagina, as well as the great pelvic vessels, particularly the left common iliac vein and its confluences or malformations. Although vaginal mesh complications have been well publicized, complications from intra-abdominal mesh placed by means of MIS for POP repair are limited. Compared to vaginally placed mesh, MIS intra-abdominal mesh is also more durable, however it carries its unique risks associated with general anesthesia, Trendelenburg positioning and pneumoperitoneum [42]. Otherwise, the unique risks are poorly published, with osteomyelitis only reported in several cases. There is limited guidance on how to approach an abdominal mesh complication. Expectant management can begin with antibiotics. Surgery is recommended if clinical status acutely worsens, symptoms are severe, if the patient has failed multiple attempts at mesh revision, or with new onset neurological deficits [18, 57, 61]. Although G. Willy Davila’s report provides recommendations for managing small vs. large vaginal mesh exposures as well as its contractions and infection [50], Level I evidence are still lacking on how to manage infected mesh deep in the sacral region.

Advertisement

3. Conclusion

This case series presents an example of three patients who underwent open abdominal, laparoscopic and robotic POP repair several years prior, and subsequently developed mesh related osteomyelitis requiring complete removal of mesh. Of particular significance is the delayed onset of osteitis presenting up to a decade after mesh placement. This can be a challenge when patients are not the best historians either due to advanced age or other comorbidities. With an increased demand for POP prolapse surgeries as the population ages, mesh-related osteomyelitis will become more prevalent. Prospective randomized studies could help determine the ideal protocols for treatment of foreign body osteomyelitis. This short case series illustrates that mesh-related osteomyelitis after POP surgeries carries significant morbidity, its management can be technically challenging and should not be undertaken lightly. However it also demonstrates that mesh removal by means of MIS in the hands of an experienced surgical team utilizing DaVinci Robotic System is a good option and may be the preferred option among these challenging patients [52, 56].

References

  1. 1.Arthure, savage uterine prolapse and prolapse of the vaginal vault treated by sacral hysteropexy. The Journal of Obstetrics and Gynaecology of the British Empire. 1957;64:355-360
  2. 2.Lane FE. Repair of post-hystectomy vaginal vault prolapse. Obstetrics & Gynecology. 1962;20:72-77
  3. 3.Anger T, Mueller R, Tarnay R, et al. Robotic compared with laparoscopic Sacrocolpopexy: A randomized controlled trial. Obstetrics & Gynecology. 2014;123(1):5-12. DOI: 10.1097/AOG.0000000000000006
  4. 4.Collins SA, Tulikangas PK, O’Sullivan DM. Effect of surgical approach on physical activity and pain control after sacral colpopexy. (Report). American Journal of Obstetrics and Gynecology. 2012;206(5):438.e1-438.e6
  5. 5.Shepherd JP, Higdon HL 3rd, Stanford EJ, Mattox TF. Effect of suture selection on the rate of suture or mesh erosion and surgery failure in abdominal sacrocolpopexy. Female Pelvic Medicine & Reconstructive Surgery. 2010;16:229-233
  6. 6.Khan A, Alperin M, Wu N, et al. Comparative outcomes of open versus laparoscopic sacrocolpopexy among medicare beneficiaries. International Urogynecology Journal. 2013;24(11):1883-1891. DOI: 10.1007/s00192-013-2088-9
  7. 7.Callewaert G, Bosteels J, Housmans S, et al. Laparoscopic versus robotic-assisted sacrocolpopexy for pelvic organ prolapse: A systematic review. Gynecological Surgery. 2016;13(2):115-123. DOI: 10.1007/s10397-016-0930-z
  8. 8.Weidner AC, Cundiff GW, Harris RL, Addison WA. Sacral osteomyelitis: An unusual complication of abdominal sacral colpopexy. Obstetrics and Gynecology. 1997;90(4 Pt 2):689-691. DOI: 10.1016/s0029-7844(97)00306-2
  9. 9.Arbel R, Lavy Y. Vaginal vault prolapse: Choice of operation. Best Practice & Research Clinical Obstetrics & Gynaecology. 2005;19(6):959-977. DOI: 10.1016/j.bpobgyn.2005.08.011
  10. 10.McDermott C, Park J, Terry C, Woodman P, Hale D. Laparoscopic sacral colpoperineopexy: Abdominal versus abdominal–vaginal posterior graft attachment. International Urogynecology Journal. 2011;22(4):469-475. DOI: 10.1007/s00192-010-1302-2
  11. 11.Nezhat C. Laparoscopic sacral colpopexy for vaginal vault prolapse. Obstetrics and Gynecology. 1994;84:885-888
  12. 12.Di Marco DS, Chow GK, Gettman MT, Elliott DS. Robotic-assisted laparoscopic sacrocolpopexy for treatment of vaginal vault prolapse. Urology (Ridgewood, NJ). 2004;63(2):373-376. DOI: 10.1016/j.urology.2003.09.033
  13. 13.Marco D, Chow, Gettman, et al. Robotic-assisted laparoscopic sacrocolpopexy for treatment of vaginal vault prolapse. Urology. 2004;63:373
  14. 14.Geller EJ, Siddiqui NY, Wu JM, Visco AG. Short-term outcomes of robotic sacrocolpopexy compared with abdominal sacrocolpopexy. Obstetrics and Gynecology. 2008;112(6):1201-1206. DOI: 10.1097/AOG.0b013e31818ce394
  15. 15.Margulies RU, Lewicky-Gaupp C, Fenner DE, et al. Complications requiring reoperation following vaginal mesh kit procedures for prolapse. American Journal of Obstetrics and Gynecology. 2008;199(678):e1-e4
  16. 16.Mowat A, Maher C, Ballard E. Surgical outcomes for low-volume vs high-volume surgeons in gynecology surgery: A systematic review and meta-analysis. American Journal of Obstetrics and Gynecology. 2016;215(1):21-33. DOI: 10.1016/j.ajog.2016.02.048
  17. 17.Toomey P, Teta A, Patel K, Ross S, Rosemurgy A. High-volume surgeons vs high-volume hospitals: Are best outcomes more due to who or where? The American Journal of Surgery. 2016;211(1):59-63. DOI: 10.1016/j.amjsurg.2015.08.021
  18. 18.Bergersen A, Hinkel C, Funk J, Twiss CO. Management of vaginal mesh exposure: A systematic review. Arab Journal of Urology. 2019;17(1):40-48. DOI: 10.1080/2090598X.2019.1589787
  19. 19.Update on the Safety and Effectiveness of Transvaginal Placement for Pelvic Organ Prolapse, July 2011 [Internet]. U.S. Food and Drug Administration; 2020. Available from:https://www.fda.gov/media/81123/download
  20. 20.Barbalat Y, Tunuguntla H. Surgery for pelvic organ prolapse: A historical perspective. Current Urology Reports. 2012;13(3):256-261. DOI: 10.1007/s11934-012-0249-x
  21. 21.Ortman J, Velkoff A. An Aging Nation: The Older Population in the United States. Washington, D.C: U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau; 2014. Available from:https://www.census.gov/library/publications/2014/demo/p25-1140.html
  22. 22.Kirby A, Luber K, Menefee S. An update on the current and future demand for care of pelvic floor disorders in the United States. American Journal of Obstetrics and Gynecology. 2013;209(6):584.e1-584.e5. DOI: 10.1016/j.ajog.2013.09.011
  23. 23.Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S. women: 2010 to 2050. Obstetrics and Gynecology. 2009;114(6):1278-1283
  24. 24.FDA Orders Makers of Women’s Surgical Mesh to Stop Selling the Products. Dow Jones Institutional News. 2019. Available from:http://search.proquest.com/docview/2210255794/
  25. 25.Gornall J. Vaginal mesh implants: Putting the relations between UK doctors and industry in plain sight. BMJ: British Medical Journal (Online). 2018;363. DOI: 10.1136/bmj.k4164
  26. 26.Roovers JP. Collaboration with the mesh industry: Who needs who? International Urogynecology Journal. 2016;27(9):1293-1295. DOI: 10.1007/s00192-016-3075-8. Epub 2016 Jul 13
  27. 27.Sung VW, Rogers RG, Schaffer JI, Balk EM, Uhlig K, Lau J, et al. Graft use in transvaginal pelvic organ prolapse repair: A systematic review. Obstetrics & Gynecology. 2008;112(5):1131-1142. DOI: 10.1097/AOG.0b013e3181898ba9
  28. 28.Abed et al. Incidence and management of graft erosion, wound granulation, and dyspareunia following vaginal prolapse repair with graft materials: A systematic review. International Urogynecology Journal. 2011;22(7):789-798
  29. 29.Caquant F, Collinet P, Debodinance P, Berrocal J, Garbin O, Rosenthal C, et al. Safety of trans vaginal mesh procedure: Retrospective study of 684 patients. The Journal of Obstetrics and Gynaecology Research. 2008;34(4):449-456. DOI: 10.1111/j.1447-0756.2008.00820.x
  30. 30.Aungst MJ, Friedman EB, von Pechmann WS, Horbach NS, Welgoss JA. De novo stress incontinence and pelvic muscle symptoms after transvaginal mesh repair. American Journal of Obstetrics and Gynecology. 2009;201(1):73.e1-73.e7. DOI: 10.1016/j.ajog.2009.02.028. Epub 2009 Apr 23
  31. 31.Rabin RC. Trial of Synthetic Mesh in Pelvic Surgery Ends Early. The New York Times; 2010. Available from:http://www.nytimes.com/2010/10/26/health/research/26complications.html?_r=0
  32. 32.The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Polypropylene Vaginal Mesh Implants for Vaginal Prolapse. Renewed November 2016. Available from:www.ranzcog.edu.au/getattachment/Statements-Guidelines/Gynaecology/Polypropylene-Vaginal-Mesh-Implants-for-Vaginal-Pr/Polypropylene-vaginal-mesh-implants-for-vaginal-prolapse-(C-Gyn-20)-Review-November-2016.pdf?lang=en-AU&ext=.pdf
  33. 33.Meier BFDA. Orders Surgical Mesh Makers to Study Risks. The New York Times; 2012. Available from:http://www.nytimes.com/2012/01/05/health/research/fda-orders-more-study-on-surgical-mesh-risks.html[Accessed: December 31, 2012]
  34. 34.Consumer Reports Magazine Staff. Dangerous devices: Most medical implants have never been tested for safety. Consumer Reports. 2012:24Y29
  35. 35.Wu Y, Welk B. Revisiting current treatment options for stress urinary incontinence and pelvic organ prolapse: A contemporary literature review. Research and Reports in Urology. 2019;11:179-188. Available from:https://doaj.org/article/85f77c35fd9c436fb6c15cfae9e27e56
  36. 36.Cornella J. Management of stress urinary incontinence. Reviews in Urology. 2004;6(Suppl. 5):S18-S25
  37. 37.Douseki T, Tanaka A. Self-powered wireless disposable sensor for welfare application. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 2013;2013:1664-1667. DOI: 10.1109/EMBC.2013.6609837
  38. 38.Wright T. Adult Incontinence Market is Baby Booming. Nonwovens Industry. 2013. Available from:https://www.nonwovens-industry.com/the-ai-market-is-baby-booming
  39. 39.Barber MD, Brubaker L, Burgio KL, et al. Comparison of 2 transvaginal surgical approaches and perioperative behavioral therapy for apical vaginal prolapse: The OPTIMAL randomized trial. Journal of the American Medical Association. 2014;311(10):1023-1034. DOI: 10.1001/jama.2014.1719
  40. 40.Muffly TM, Diwadkar GB, Paraiso MF. Lumbosacral osteomyelitis after robot-assisted total laparoscopic hysterectomy and sacral colpopexy. International Urogynecology Journal. 2010;21(12):1569-1571. DOI: 10.1007/s00192-010-1187-0. Epub 2010 Jun 8
  41. 41.Hart SR, Weiser EB, Hart SR, Weiser EB. Abdominal sacral colpopexy mesh erosion resulting in a sinus tract formation and sacral abscess. Obstetrics and Gynecology. 2004;103:1037-1040
  42. 42.Linder B, Elliott D. Robotic Sacrocolpopexy: How does it compare with other prolapse repair techniques? Current Urology Reports. 2013;14(3):235-239. DOI: 10.1007/s11934-012-0299-0
  43. 43.Cho E, Um M, Kim S, Jung H. A study on laparoscopic sacral colpopexy for uterine prolapse. Journal of Menopausal Medicine. 2017;23(3):190-195. DOI: 10.6118/jmm.2017.23.3.190
  44. 44.Mattimore J, Cheetham P, Katz A. The history of pelvic organ prolapse from antiquity to present day. Journal of Urology. 2015;193(4):E590-E591
  45. 45.Crosby EC, Abernethy M, Berger MB, et al. Symptom resolution after operative management of complications from transvaginal mesh. Obstetrics and Gynecology. 2014;123:134-139
  46. 46.Deval B, Fauconnier A, Repiquet D, Liou Y, Montuclard B, Fritel X, et al. Traitement chirurgical des prolapsus génito-urinaires par voie abdominale. A propos d’une série de 232 cas [Surgical treatment of genitourinary prolapse by the abdominal approach. Apropos of a series of 232 cases]. Annales de Chirurgie. 1997;51(3):256-265
  47. 47.Daneshgari F, Hijaz A, Moore C, Aleman M, Kaouk J. Robotic laparoscopic sacrocolpopexy with or without uteropexy. Journal of Urology. 2005;173(4):136-136
  48. 48.Munz Y, Moorthy K, Kudchadkar R, Hernandez J, Martin S, Darzi A, et al. Robotic assisted rectopexy. The American Journal of Surgery. 2004;187(1):88-92. DOI: 10.1016/j.amjsurg.2002.11.001
  49. 49.Banerjie C, Noe K. Laparoscopic pectopexy: A new technique of prolapse surgery for obese patients. Archives of Gynecology and Obstetrics. 2011;284(3):631-635. DOI: 10.01107/s00404-010-1687-7
  50. 50.Smith A, Davila G. Take this simplified approach to correcting exposure of vaginal mesh: By proceeding stepwise, uncomplicated exposures lend themselves to the generalist’s care. Here are management pearls, cautions, and gauges of success (Surgical Techniques) (case study). OBG Management. 2011;23(7):29-40
  51. 51.Maher C, Feiner B, Baessler K, et al. Surgical management of pelvic organ prolapse in women. Cochrane Database of Systematic Reviews. 2010;4:CD004014
  52. 52.Chamsy D, Lee T, Chamsy D. Laparoscopic excision of sacrocolpopexy mesh. Journal of Minimally Invasive Gynecology. 2014;21(6):986-986. DOI: 10.1016/j.jmig.2014.07.011
  53. 53.Müller P, Berchtold C, Kuemmerli C, Ruzza C, Z’Graggen K, Steinemann D. Spondylodiscitis after minimally invasive recto- and colpo-sacropexy: Report of a case and systematic review of the literature. Journal of Minimal Access Surgery. 2020;16(1):5-12. DOI: 10.4103/jmas.JMAS_235_18
  54. 54.Amid P. Classification of biomaterials and their relative complications in an abdominal wall hernia surgery. Hernia. 1997;1:15-21. DOI: 10.1007/BF02426382
  55. 55.Zambon J, Badlani G. Vaginal mesh exposure presentation, evaluation, and management. Current Urology Reports. 2016;17(9):1-8. DOI: 10.1007/s11934-016-0617-z
  56. 56.Heisler CA, Casiano ER, Klingele CJ, Gebhart JB, Trabuco EC. Ureteral injury during vaginal mesh excision: Role of prevention and treatment options. American Journal of Obstetrics and Gynecology. 2012;207(6):e3-e4. DOI: 10.1016/j.ajog.2012.09.010
  57. 57.Rardin C, Duckett J, Milani A, Paván L, Rogo-Gupta L, Twiss C. Joint position statement on the management of mesh-related complications for the FPMRS specialist. International Urogynecology Journal. 2020;31(4):679-694. DOI: 10.1007/s00192-020-04248-x
  58. 58.Management of mesh and graft complications in gynecologic surgery. Obstetrics and Gynecology. 2017;129(4):E102-E108
  59. 59.Skoczylas L, Shepherd J, Smith K, Lowder J. Managing mesh exposure following vaginal prolapse repair: A decision analysis comparing conservative versus surgical treatment. International Urogynecology Journal. 2013;24(1):119-125. DOI: 10.1007/s00192-012-1847-3
  60. 60.Abbott S, Unger CA, Evans JM, et al. Evaluation and management of complications from synthetic mesh after pelvic reconstructive surgery: A multicenter study. American Journal of Obstetrics and Gynecology. 2014;210:163.e1-163.e8
  61. 61.Urinary incontinence and pelvic organ prolapse in women: Management. NICE guideline. National Institute for Health and Care Excellence. 2019. Available from:www.nice.org.uk/guidance/ng123/resources/urinary-incontinence-and-pelvic-organ-prolapse-in-women-management-pdf-66141657205189[Accessed: April 22, 2019]
  62. 62.Spelzini F, Frigerio M, Manodoro S, Interdonato M, Cesana M, Verri D, et al. Modified McCall coldoplasty versus Shull suspension in pelvic prolapse primary repair: A retrospective study. International Urogynecology Journal. 2017;28(1):65-71. DOI: 10.1007/s00192-016-3016-6
  63. 63.Jenson MDAV, Scranton R, Antosh DD, Simpson RK. Lumbosacral osteomyelitis and discitis with Phlegmon following laparoscopic sacral colpopexy. Cureus. 2016;8(7):e671. DOI: 10.7759/cureus.671. Erratum in: Cureus. 2016;8(10):c5

Written By

Adriana Fulginiti, Frank Borao, Martin Michalewski and Robert A. Graebe

Submitted: October 2nd, 2021Reviewed: October 20th, 2021Published: March 16th, 2022